Local Community Support Advances Silver-Dominant Maria Norte Toward Access and Development ExecutionVANCOUVER, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rio Silver Inc. (“Rio Silver” or the “Company”) (TSX-V: RYO | OTC: RYOOF) is pleased to announce that it has received permission from the local community to commence planned site activities at its Maria Norte Project in Peru. The agreement allows the Company to begin establishing the necessary infrastructure to efficiently start exploration and de ...

Figure 1 MD Projects-Eeyou Istchee James Bay Figure 2 Caniaspic Au 2025 Results Figure 3 Caniapisc Au Planned IP Figure 4 Samples 2025 Figure 5 Samples 2025 Figure 6 Samples 2025 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an induced polarization ground (“IP’) geophysical survey on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions. The Caniapisc Au project is wholly ...

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock. Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of April to mid-M ...

JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows: Leerink Partners Global Healthcare ConferenceMarch 8 - 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside ch ...

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations w ...

Rare earth element and niobium anomalies found in sediments and surrounding rocksVancouver, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Initial prospecting results and geological observations suggest that the broader area encompassing North American Niobium and Critical Minerals Corp.’s (CSE: NIOB) (OTCQB: NIOMF) (FSE: KS82.F) Bardy, Blanchette and Sabot projects in Québec may be comparable in style to the large rare-earth element (REE) deposits found in Greenland. As such, the Company has begun a t ...

Giant Containers to design and build critical infrastructure and community amenities for transformative urban state park spanning northern New JerseyCONROE, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- via IBN — Olenox Industries Inc. (NASDAQ: OLOX) (“Olenox Industries” or the “Company”) today announced that its subsidiary, Giant Containers, has been selected to provide design and construction services for critical infrastructure and amenities as part of the nearly one-mile Newark segment of New Jersey’s newest ...

HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only we ...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; e ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATESTORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Consolidated Lithium Metals Inc. (TSXV: CLM | FRA: Z36 | OTCQB: JORFF) (“CLM” or the “Company”) announces today that it intends to complete a non-brokered private placement offering (the “Offering”) of securities of the Company for aggregate gross proceeds to the Company of up to $17,070,000, in a combination of: a) up to 31,250,000 units of the Company that will be issued ...